Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir

AIDS Research and Human Retroviruses

Volumn 29, Issue 4, 2013, Pages 665-672

  Sherman, Amy C ^a   Trehanpati, Nirupama ^b   Daucher, Marybeth ^a   Davey, Richard T ^a   Masur, Henry ^c   Sarin, Shiv Kumar ^b   Kottilil, Shyam ^a   Kohli, Anita ^a,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD4+CD25 +FOXP3+ T LYMPHOCTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ANTIGENS, CD274; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; VIRAL LOAD; VIREMIA;

EID: 84876249437     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0320     Document Type: Article

References (39)

1. Shi J ZL, Liu S, and Xie WF: A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005(92):607-612.
2. WHO: Fact Sheet, Hepatitis B: World Health Organization (WHO) Fact Sheets.
3. WHO: AIDS Epidemic Update.
4. Alter M: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(Suppl 1):S6-S9.
5. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
6. Thio CL, Skolasky R Jr, Phair J, Visscher B, Muñoz A, and Thomas DL: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360(9346):1921-1926.
7. Rector WGS, Horsburgh C, Penley K, Cohn D, and Judson F: Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to HIV. Am J Gastroenterol 1988(83): 262-266.
8. Colin J and Loriot M: Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310.
9. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J: Cirrhosis Asian Lamivudine Multicentre Study Group. N Engl J Med. 2004;351:1521-1531.
10. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, and Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119(4):312-323.
11. Akbar F, Yoshida O, Abe M, Hiasa Y, and Onji M: Engineering immune therapy against hepatitis B virus. Hepatol Res 2007;37(Suppl 3):S351-356.
12. Chen M, Zhang D, Zhen W, et al.: Characteristics of circulating T cell receptor gamma-delta T cells from individuals chronically infected with hepatitis B virus (HBV): An association between V(delta)2 subtype and chronic HBV infection. J Infect Dis 2008;198(11):1643-1650.
13. Schlaak JF, Tully G, Lohr HF, Gerken G, and Meyer zum Buschenfelde KH:HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and antiinflammatory cytokines. Clin Exp Immunol 1999;115(3):508-514.
14. Guoping Peng SL, Wei W, Zhen S, Yiqiong C, and Zhi C: Circulating CD4+ CD25 + regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008;123:57-64.
15. Jeroen N, van der Molenl RG, Kuipersa EJ, Kustersa JG, and Janssen HLA: Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007;361(1):141-148.
16. Walker MR, Gersuk VH, Bènard A, Van Landeghen M, Buckner JH, and Ziegler SF: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+ CD25 - T cells. J. Clin. Invest 2003;112:1437.
17. Franzese OKP, Gehring AJ, Gotto J, Williams R, Maini MK, and Bertoletti A: Modulation of the CD8 + T-cell response by CD4+ CD25 + regulatory T cells in patients with hepatitis B virus infection. J Virol 2005(79):3322-3328.
18. Stoop JN vdMR, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, and Janssen HL: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771-778.
19. Greenwald RJ, Freeman GJ, and Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005;23:515-548.
20. Okazaki T and Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006;27:195-201.
21. Fisicaro P, Valdatta C, Massari M, et al.: Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138(2):682-693.
22. Zhang Z, Zhang JY, Wherry EJ, et al.: Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 2008;134(7):1938-1949.
23. Raziorrouh B, Schraut W, Gerlach T, et al.: The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010;52:1935-1948.
24. Crane M, Sirivichayakul S, Chang JJ, et al.: No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol 2010;84(6):2657-2665.
25. Zhang HH, Guo F, Fei R, et al.: [Inhibition of CD4 + CD25 + regulatory T cells in chronic hepatitis B patients]. Zhonghua Yi Xue Za Zhi 2008;88(8):511-515.
26. Peng G, Li S, Wu W, Sun Z, Chen Y, and Chen Z: Circulating CD4 + CD25 + regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008;123(1):57-65.
27. Nan XP, Zhang Y, Yu HT, et al.: Circulating CD4 + CD25high regulatory T cells and expression of PD-1 and BTLA on CD4 + T cells in patients with chronic hepatitis B virus infection. Viral Immunol 2010;23(1):63-70.
28. TrehanPati N, Geffers R, Sukriti, et al.: Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology 2009;49(3):781-790.
29. Miyaaki H, Zhou H, Ichikawa T, et al.: Study of livertargeted regulatory T cells in hepatitis B and C virus in chronically infected patients. Liver Int 2009;29(5):702-707.
30. Rushbrook SM, Hoare M, and Alexander GJ: T-regulatory lymphocytes and chronic viral hepatitis. Expert Opin Biol Ther 2007;7(11):1689-1703.
31. Furuichi Y, Tokuyama H, Ueha S, Kurachi M, Moriyasu F, and Kakimi K: Depletion of CD25 + CD4+ T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization. World J Gastroenterol 2005; 11(24):3772-3777.
32. Boni C, Penna A, Bertoletti A, et al.: Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39(4):595-605.
33. Kondo Y, Asabe S, Kobayashi K, et al.: Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol 2004;74(3):425-433.
34. Pan XC, Yang F, and Chen M: [The effect of telbivudine on peripheral blood CD4+ CD25 + regulatory T cells and its significance in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi 2008;16(12):885-888.
35. Hui CK and Lau GK: Advances in immunomodulating therapy of HBV infection. Int J Med Sci 2005;2(1):24-29.
36. Zhang W, Dong SF, Sun SH, Wang Y, Li GD, and Qu D: Coimmunization with IL-15 plasmid enhances the longevity of CD8 T cells induced by DNA encoding hepatitis B virus core antigen. World J Gastroenterol 2006;12(29):4727-4735.
37. Kinter AL, Godbout EJ, McNally JP, et al.: The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008;181(10):6738-6746.
38. Radziewicz H, Dunham RM, and Grakoui A: PD-1 tempers Tregs in chronic HCV infection. J Clin Invest 2009;119(3): 450-453.
39. Hoyos V, Savoldo B, Quintarelli C, et al.: Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010;24(6):1160-1170.